NO154521B - Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater. - Google Patents
Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater. Download PDFInfo
- Publication number
- NO154521B NO154521B NO801014A NO801014A NO154521B NO 154521 B NO154521 B NO 154521B NO 801014 A NO801014 A NO 801014A NO 801014 A NO801014 A NO 801014A NO 154521 B NO154521 B NO 154521B
- Authority
- NO
- Norway
- Prior art keywords
- compound
- compounds
- preparation
- pharmaceutically acceptable
- therapeutically active
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000004615 ingredient Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 7
- -1 1-oxobutyl compound Chemical class 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 13
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960001340 histamine Drugs 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000005456 alcohol based solvent Substances 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- UVZGOOXAARJPHD-UHFFFAOYSA-N butan-2-one;methanol Chemical compound OC.CCC(C)=O UVZGOOXAARJPHD-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AMPNBNGNPLXMOP-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)acetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1C AMPNBNGNPLXMOP-UHFFFAOYSA-N 0.000 description 1
- YYEROYLAYAVZNW-UHFFFAOYSA-N 2-methyl-2-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC=C1 YYEROYLAYAVZNW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical class C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- BKGNRWXKVMPQJE-UHFFFAOYSA-N ethyl 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoate Chemical compound C1=CC(C(C)(C)C(=O)OCC)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 BKGNRWXKVMPQJE-UHFFFAOYSA-N 0.000 description 1
- XAGIKTXVRKZQRW-UHFFFAOYSA-N ethyl 2-[4-[4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butanoyl]phenyl]-2-methylpropanoate;hydrochloride Chemical compound Cl.C1=CC(C(C)(C)C(=O)OCC)=CC=C1C(=O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 XAGIKTXVRKZQRW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000005453 ketone based solvent Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
Foreliggende oppfinnelse angår en analogifrem-
gangsmåte for fremstilling av terapeutisk aktive, nye piperidinoalkanolderivater som er nyttige som antihistaminer, antiallergimidler og bronchodilatorer.
Beslektede piperidinderivater med antihistaminegen-
skaper er beskrevet i følgende US patentskrifter:
US-PS 3 806 526 bevilget 23. april 1974
US-PS 3 829 433 bevilget 13. august 1974
US-PS 3 862 173 beviltet 21. januar 1975
US-PS 3 878 217 bevilget 15. april 1975
US-PS 3 931 197 bevilget 6. januar 1976
US-PS 3 941 795 bevilget 2. mars 1976
US-PS 3 946 022 bevilget 23. mars 1976 og
US-PS 3 965 257 bevilget 22. juni 1976.
De nye substituerte piperidinderivater som frem-
stilles ifølge oppfinnelsen og som er anvendbare som anti-
histaminer, antiallergimidler og bronchodilatorer, represen-
teres ved formel:
hvori R er -COOH eller -COOalkyl, hvori alkylgruppen har fra 1 til 6 carbonatomer og er rettkjedet eller forgrenet,
og farmasøytisk akseptable salter derav.
Illustrative eksempler på rettkjedede eller for-
grenede alkylgrupper med fra 1 til 6 carbonatomer er methyl,
ethyl, n-propyl, isopropyl, n-butyl, sekundær butyl, tertiær butyl, n-pentyl, neopentyl og n-hexyl.
En særlig foretrukket forbindelse er 4-[4-[4-
(hydroxydifenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-a,a-dimethylbenzeneddiksyre.
Oppfinnelsen innbefatter også fremstilling av farmasøytisk akseptable salter av forbindelsene av de ovenfor angitte formler. Farmasøytisk akseptable syreaddisjons-salter av forbindelsene er de av en hvilken som helst egnet uorganisk eller organisk syre.
Forbindelsene som fremstilles ifølge oppfinnelsen, er anvendbare som antihistaminer, antiallergimidler og bronchodilatorer og kan administreres alene eller med egnede farmasøytiske bærere, og kan være i fast eller flyt-ende form slik som tabletter, kapsler, pulvere, løsninger, suspensjoner eller emulsjoner.
Forbindelsene kan administreres oralt, parenteralt, for eksempel subcutant, intravenøst, intramuskulært, intra-peritonealt, ved intranasal drypping eller ved påføring til slimhinner slik som i nese, hals eller bronkier, for eksempel i en aerosolspray inneholdende små partikler av en forbindelse fremstilt ifølge oppfinnelsen i en spray eller i tørt pulver.
Mengden av administrert ny forbindelse vil variere avhengig av pasienten og administreringsmåte og kan være hvilken som helst effektiv mengde. Mengden administrert ny forbindelse kan variere et vidt område for å tilveiebringe en enhetsdose i en effektiv mengde på fra 0,01 til 20 mg/kg kroppsvekt pr. dag for å oppnå den ønskede effekt. Eksempel-vis kan den ønskede antihistamin-, antiallergi- og broncho-dilatoreffekt oppnås ved forbruk av en enhetsdose slik som en tablett inneholdende 1 til 50 mg av en ny forbindelse ifølge oppfinnelsen tatt 1 til 4 ganger daglig.
De faste enhetsdoseringsformer kan være av konven-sjonell type. Således kan den faste form være en kapsel som kan være av vanlig gelatintype inneholdende en ny forbindelse og en bærer, smøremidler og inerte fyll-
stoffer slik som lactose, sucrose eller maisstivelse. I en annen utførelsesform tabletteres de nye forbindelser med kon-vensjonelle tablettbaser slik som lactose, sucrose eller
maisstivelse i kombinasjon med bindemidler slik som acacia, maisstivelse eller gelatin, oppløsnende midler slik som maisstivelse, potetstivelse eller algininsyre, og et smøremiddel slik som stearinsyre eller magnesiumstearat.
Forbindelsene sem fremstilles ifølge oppfinnelsen, kan også administreres i injiserbare doser ved oppløsning eller suspensjon av forbindelsene i et fysiologisk akseptabelt fortynningsmid-del med en farmasøytisk bærer som kan være en steril væske slik som vann og oljer, med eller uten tilsetning av et over-flateaktivt middel og andre farmasøytisk akseptable hjelpestoffer. Som illustrative eksempler på oljer kan nevnes de av petroleum, animalsk, vegetabilsk eller syntetisk opprin-nelse, for eksempel peanøttolje, soyabønneolje eller mineral-olje. Generelt er vann, saltvann, vandig dextrose og beslektede sukkerløsninger og glycoler slik som propylen-glycol eller polyethylenglycol, foretrukne væskebærere, i særdeleshet for injiserbare løsninger.
For bruk som aerosoler kan forbindelsene sam fremstilles ifølge oppfinnelsen i løsning eller suspensjon pakkes i en komprimert aerosolbeholder sammen med egnede drivmidler, for eksempel hydrocarbondrivmidler slik som propan, butan eller iso-butan med de vanlige hjelpestoffer som kan være nødvendig eller ønskelig. Forbindelsene kan også administreres i ikke komprimert form slik som i en forstøver.
Uttrykket pasient som anvendt her, menes å omfatte varmblodige dyr, fugler, pattedyr, for eksempel mennesker, katter, hunder, hester, sauer, kveg, griser, lam, rotter, mus og marsvin.
For å demonstrere anvendeligheten av forbindelsene ifølge oppfinnelsen angis at 4-[4-[4-(hydroxydifenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-a,a-dimethylbenzeneddiksyre i en konsentrasjon på 1 x 10 gir en signifikant reduksjon i histamin-indusert muskelkontraksjon i isolert marsvin ileum-muskel.
Den etterfølgende forsøksrapport illustrerer aktiviteten av de nye forbindelser.
Forsøksrapport
Metoder
Hannmarsvin, 290-800 g, ble avlivet ved halsvridning.
Et stykke av ileum, 20 cm i lengde, ble fjernet fra marsvinet og anbragt i en skål inneholdende Tyrodes løsning. Ileum ble deretter bundet ved begge ender og anbragt i et 25 ml organbad med en ende av muskelen bundet til en muskelholder og den andre ende koblet til en Grass FT03 kraftforskyvnings-transduktor koblet med en sølvfjær for nedtegnelse av iso-tonisk kontraktilitet. Tyrodes løsning i organbadet ble holdt ved 37°C og ble boblet med en blanding av 95% oxygen-5% carbon-dioxyd og hadde følgende sammensetning i mM: NaCl 136,89;
KC1 2,68; CaCl2 1,80; MgCl2 1,05; NaH^PO^ 0,42; NaHC03,
11,90; og dextrose 5,55. Ileumremsene ble i begynnelsen be-lastet med 0,5 g strekk og fikk ekvilibreres i minimum 30 minutter før starten på forsøket.
Dose-responsforsøket ble utført ved tilsetning av agonisten (histamin) kumulativt til organbadet. Som en generell prosedyre ble et begynnelsesdose-responsforsøk etterfulgt av et andre som ble betraktet som kontrollen. Etter at histamindose-responskontrollforsøkene var fullført, ble remsene deretter inkubert med bærer (ethanol, 25^ul/25 ml bad), forbindelse I (kjent forbindelse fra MO patent 140 057), a- (p-t-butyl-fenyl)-4-(a-hydroxy-a-fenylbenzyl)-1-piperidinbutanol (3,162 x 10 —8M) og forbindelse II, fremstilt ifølge oppfinnelsen, 4-[4-[4-(hydroxydifenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-a,a-
_7
dimethylbenzeneddiksyre (10 M) i 50 minutter. Dette tids-rom ble vist å være tilstrekkelig for å gi full antihistamin-effekt for forbindelse I. Histamindose-responsforsøkene ble deretter utført i nærvær av testforbindelsene.
Etter fullførelse av histamindose-responsforsøkene ble vevet umiddelbart vasket to ganger med frisk Tyrodes løsning under anvendelse av 180 ml for hver vasking og ble vasket igjen én gang 15 minutter senere. Den gjenværende anti-histamineffekt i det behandlede ileum ble bestemt ved ut-fordring av vevet med histamin 30, 60, 90 og 120 minutter senere, og med samme vaskinger med Tyrodes løsning umiddelbart deretter og 15 minutter etter hvert histamindose-responsforsøk.
Graden av forandringen av histamindose-responsen ble uttrykt som et doseforhold beregnet fra forholdet mellom ED^-verdiene (den konsentrasjon som er nødvendig for å gi
50% av den maksimale kontraktile respons). Hastighetskonstanten, k^ for assosiasjon og k2 for dissosiasjon ble bestemt i henhold til ligningen beskrevet av Paton og Rang:
hvori Pfc og Pg er den fraksjon av reseptor som er okkupert av antagonisten ved tid t og ved likevekt og kan bestemmes ved følgende forhold: p = (doseforhold -1)/doseforhold. Således kan k-, bestemmes grafisk fra hellingen av linjen nedtegnet fra p mot t på semi-logpapir. Likevektskonstanten, Ke, ble bestemt etter 50 minutters inkubering under anvendelse av ligningen beskrevet av Makay: Ke = X/ (doseforhold -1) hvori X er konsentrasjonen av antagonisten. Hastighetskonstanten k^ beregnes deretter fra forholdet k^ = k2/Ke. pA2~verdiene beregnes deretter ved omdannelsen: pA0 = -log Ke. For be-regning av doseforholdet ble enhver forandring av histamindose-responskurvene fremkalt av testlegemidlene korrigert for forandringene fremkalt av bæreren (ethanol).
Testforbindelser
Følgende testforbindelser ble anvendt ved denne under-søkelse: forbindelse I og forbindelse II. Begge forbindelser ble fremstilt i ethanol som en lOyUmol/rfil løsning og ble for-tynnet til den ønskede styrke for bruk.
Statistisk analyse
Dataene er angitt som gjennomsnitt - S.E. Student's t-test ble anvendt for å sammenligne signifikansen av for-skjellene. En sannsynlighet på mindre enn 0,05 ble betraktet å være statistisk signifikant.
Tabell 1 viser hastighetskonstantene for assosiasjon (k^ og dissosiasjon (k2), likevektsdissosiasjonskonstant (Ke) og pA0-verdiene. Rekkefølgen for k^ og k9 er forbindelse II og forbindelse I. pA0-verdiene for forbindelse I og forbindelse II er 8,83 - 0,05 (X - S.E., n = 6) og 8,32 - 0,09
(n = 5). Således assosierer og dissosierer forbindelse II hurtigere enn forbindelse I.
Analogifremgangsmåten ifølge oppfinnelsen er kjennetegnet ved at (a) for fremstilling av forbindelser av formel I hvor er -COOH eller -COOalkyl, reduseres den tilsvarende 1-oxobutylforbindelse etterfulgt, om ønsket, av basehydrolyse, (b) når et farmasøytisk akseptabelt salt ønskes, at den således dannede forbindelse omsettes med en farmasøytisk akseptabel syre eller base.
Reaksjonen er illustrert ved følgende reaksjons-skjemaer:
Reduksjonen av l-oxobutylforbindelsen under anvendelse av f.eks. natriumborhydrid eller kaliumborhydrid utføres i lavere alko-holløsningsmidler slik som methanol, ethanol, isopropylalkohol eller n-butanol. Når lithiumaluminiumhydrid eller diboran anvendes som reduksjonsmiddel, er egnede løsningsmidler ethere, for eksempel diethylether, tetrahydrofuran eller dioxan. Disse reduksjoner utføres ved temperaturer varierende fra 0 til løsningsmidlets tilbakeløps-temperatur, og reaksjonstiden varierer fra 1/2 til 8 timer. Katalytisk reduksjon kan også anvendes ved fremstilling av forbindelsene som vist i skjema I og II under anvendelse av for eksempel Raney-nikkel, palla-dium, platina eller rhodiumkatalysatorer i lavere alkoholløs-ningsmidler slik som methanol, ethanol, isopropylalkohol eller n-butanol eller eddiksyre eller vandige blandinger derav, eller ved anvendelse av aluminiumisopropoxyd i isopropylalkohol. Reduksjonen under anvendelse av natriumborhydrid fore-trekkes i forhold til katalytisk reduksjon ved fremstilling av for eksempel forbindelse (VIII) eller (X). Basehydrolyse av forbindelsene av formel (VIII) til forbindelser av formel (X) oppnås etter velkjente metoder innen faget, f.eks. ved behandling med en uorganisk base slik som natriumhydroxyd eller kaliumhydroxyd i et vandig lavere alkoholisk løsningsmiddel slik som vandig methanol, ethanol, isopropylalkohol eller n-butanol ved tilbakeløpstemperaturer i fra 1/2 til 12 timer. Ketonforbindelsene anvendt her som utgangsmateri-aler, dvs. forbindelser (I) i reaksjonsskjerna I, forbindelser (4) og (8) i reaksjonsskjerna II, fremstilles ved alkylering av et substituert piperidinderivat av formel med et uj-haloalkylsubstituert fenylketon av formel hvori halo er et halogenatom slik som klor, brom eller jod, og R, 5 er -COOalkyl hvori alkylgruppen har fra 1 til 6 carbonatomer og er rettkjedet eller forgrenet. Når R i utgangs-forbindelsen er -COOH, etterfølges alkyleringsreaksjonen av basehydrolyse. Alkyleringsreaksjonen utføres i et egnet løsnings-middel, fortrinnsvis i nærvær av en base, og eventuelt i nærvær av en katalytisk mengde av kaliumjodid i fra 4 til 120 timer ved temperaturer på ca. 70° C til løsningsmidlets tilbakeløpstemperatur. Egnede løsningsmidler for alkyleringsreaksjonen innbefatter alkoholløsningsmidler slik som methanol, ethanol, isopropylalkohol eller n-butanol, ketonløs-ningsmidler slik som methylisobutylketon, hydrocarbonløs-ningsmidler slik som benzen, toluen eller xylen, halogenerte hydrocarboner slik som klorbenzen eller methylenklorid eller dimethylformamid. Egnede baser for alkyleringsreaksjonen innbefatter uorganiske baser, for eksempel natriumbicarbonat, kaliumcarbonat eller kaliumbicarbonat, eller organiske baser slik som trialkylamin, for eksempel triethylamin eller pyri-din, eller et overskudd av en forbindelse av formel XIV kan anvendes. Basehydrolyse av forbindelsene hvori R^j. er -COOalkyl til tilsvarende forbindelser hvori R^ er -COOH, oppnås ved behandling med en uorganisk base slik som natriumhydroxyd i en vandig lavere alkohol slik som vandig methanol, ethanol, isopropylalkohol eller n-butanol ved tilbakeløps-temperatur i fra 1/2 time til 12 timer.
Forbindelsene av formel XIV er kommersielt til-gjengelige.
Forbindelsene av formel XV fremstilles ved omset-ning av en egnet rettkjedet eller forgrenet lavere alkyl-C^_g-ester av a,a-dimethylfenyleddiksyre som er kjent innen faget eller fremstilles etter velkjente metoder, med en forbindelse av formel XVII hvori halo er som ovenfor angitt, under generelle Friedel-Crafts acyleringsbetingelser. Reaksjonen utføres i et løsningsmiddel slik som carbondisulfid, tetraklorethan eller nitrobenzen hvor carbondisulfid er et foretrukket løsningsmiddel. Reaksjonstiden varierer fra 1/2 time til 8 timer, fortrinnsvis 3-5 timer, og reaksjons-temperaturen varierer fra 0 til 25°C.
Forbindelsene av formel XVII er kommersielt til-gjengelige eller kan fremstilles etter velkjente metoder.
Eksempel 1
Ethyl- 4-[ 4-[ 4-( hydroxydifenylmethyl)- 1- piperidinyl]- 1-hydroxybuty1]- a, a- dimethylbenzenacetat- hydroklorid
En løsning av 5,64 g (0,01 mol) ethyl-4-[4-[4-(hydroxydifenylmethyl)-1-piperidinyl]-1-oxobutyl]-a,a-dimethyl-benzenacetat-hydroklorid i 200 ml absolutt ethanol og 50 ml methanol, og 0,5 g platinaoxyd ble hydrogenert ved ca. 3,5 kg/cm 2 i 1 time inntil infrarødt spektrum ikke viste noe tegn på ketoncarbonylfunksjon. Løsningen ble filtrert og filtra-tet konsentrert under dannelse av et residuum som ble omkry-stallisert fra butanon og methanol-butanon under dannelse av ethyl-4-[4-[4-(hydroxydifenylmethyl)-1-piperidinyl]-1-hydroxy-butyl] -a , a-dimethylbenzenacetat HC1, sm.p. 185 - 187° C. Eksempel 2
4-[ 4-[ 4-( hydroxydifenylmethyl)- 1- piperidinyl]- 1- hydroxybutyl]-g, g- dimethylbenzeneddiksyre
Til en løsning av 0,6 g ethyl-4-[4-[4-(hydroxy-dif enylmethyl )-1-piperidinyl]-1-hydroxybutyl]-a,a-dimethyl-benzenacetat i 20 ml absolutt ethanol ble tilsatt 10 ml av en 50 %-ig løsning av natriumhydroxyd. Blandingen ble kokt under tilbakeløpskjøling i 3 1/2 time og konsentrert til et fast materiale hvoretter en minimal mengde methanol ble tilsatt for å oppløse residuet. 10 % vandig HC1 ble tilsatt inntil en pH lik 7 ble nådd, methanolen ble fjernet ved fordamp-ning og 25 ml vann ble tilsatt. Det resulterende bunnfall ble omkrystaliisert fra methanol-butanon under dannelse av 4-[4-[4-(hydroxydifenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-<x,a-dimethylbenzeneddiksyre, sm.p. 195 - 197° C.
Claims (2)
1. Analogifremgangsmåte for fremstilling av terapeutisk aktive forbindelser av generell formel I
hvori R er -COOH eller -COOalkyl, hvori alkylgruppen har fra 1 til 6 carbonatomer og er rettkjedet eller forgrenet, og farmasøytisk akseptable salter derav, karakterisert ved at (a) for fremstilling av forbindelser av formel I hvor R er -COOH eller -COOalkyl, reduseres den tilsvarende 1-oxobutylforbindelse etterfulgt, om ønsket, av basehydrolyse, (b) når et farmasøytisk akseptabelt salt ønskes, at den således dannede forbindelse omsettes med en farmasøytisk akseptabel syre eller base.
2. Fremgangsmåte ifølge krav 1 ved fremstilling av 4-[4-[4-(hydroxydifenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-a,a-dimethylbenzeneddiksyre eller et farmasøytisk akseptabelt salt derav, karakterisert ved at den tilsvarende 1-oxobutylforbindelse reduseres etterfulgt av basehydrolyse.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/028,813 US4254129A (en) | 1979-04-10 | 1979-04-10 | Piperidine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
NO801014L NO801014L (no) | 1980-10-13 |
NO154521B true NO154521B (no) | 1986-06-30 |
NO154521C NO154521C (no) | 1986-10-08 |
Family
ID=21845568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO801014A NO154521C (no) | 1979-04-10 | 1980-04-09 | Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater. |
NO1998017C NO1998017I1 (no) | 1979-04-10 | 1998-05-29 | Fexofenadine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO1998017C NO1998017I1 (no) | 1979-04-10 | 1998-05-29 | Fexofenadine |
Country Status (19)
Country | Link |
---|---|
US (1) | US4254129A (no) |
JP (1) | JPS55141469A (no) |
AT (1) | AT376208B (no) |
AU (1) | AU531146B2 (no) |
BE (1) | BE882703A (no) |
CA (1) | CA1123438A (no) |
CH (1) | CH643245A5 (no) |
DE (1) | DE3007498A1 (no) |
DK (1) | DK153709C (no) |
ES (1) | ES8103735A1 (no) |
FR (1) | FR2453854A1 (no) |
IL (1) | IL59158A (no) |
IT (1) | IT1143960B (no) |
NL (2) | NL190580C (no) |
NO (2) | NO154521C (no) |
NZ (1) | NZ192653A (no) |
PH (1) | PH17023A (no) |
SE (1) | SE448726B (no) |
ZA (1) | ZA80332B (no) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240018A1 (es) * | 1987-10-07 | 1990-01-31 | Merrell Pharma Inc | Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol. |
US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
CN1053570C (zh) | 1987-10-07 | 2000-06-21 | 默尔多药物公司 | 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法 |
US4908372A (en) * | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
AR245888A1 (es) * | 1989-01-23 | 1994-03-30 | Merrell Pharma Inc | Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol. |
DE3917241A1 (de) * | 1989-05-26 | 1990-11-29 | Schaper & Bruemmer Gmbh | 4-(hydroxydiphenylmethyl)-1-piperidyl-phenylalkan-derivate |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5190029A (en) * | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
TW198008B (no) * | 1991-04-08 | 1993-01-11 | Green Cross Corp | |
HU211019B (en) * | 1991-12-02 | 1995-09-28 | Richter Gedeon Vegyeszet | Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds |
PT626968E (pt) * | 1992-02-13 | 2002-03-28 | Merrell Pharma Inc | Derivados de piperidinilo tiaciclicos |
AU671822B2 (en) * | 1992-04-10 | 1996-09-12 | Aventisub Ii Inc. | 4-diphenylmethyl piperidine derivatives and process for their preparation |
US5631375A (en) * | 1992-04-10 | 1997-05-20 | Merrell Pharmaceuticals, Inc. | Process for piperidine derivatives |
WO1993023047A1 (en) * | 1992-05-11 | 1993-11-25 | Merrell Dow Pharmaceuticals Inc. | Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient |
ATE322899T1 (de) * | 1992-08-03 | 2006-04-15 | Sepracor Inc | Terfenadin-carboxylat und die behandlung von allergischen erkrankungen |
US5654433A (en) * | 1993-01-26 | 1997-08-05 | Merrell Pharmaceuticals Inc. | Process for piperidine derivatives |
US20020007068A1 (en) * | 1999-07-16 | 2002-01-17 | D'ambra Thomas E. | Piperidine derivatives and process for their production |
DE69433346T2 (de) | 1993-06-24 | 2004-09-09 | Albany Molecular Research, Inc. | Herstellung von Verbindungen, die in der Produktion von Piperidin-Derivaten nützlich sind |
AU699559B2 (en) | 1993-06-25 | 1998-12-10 | Aventisub Ii Inc. | Novel intermediates for the preparation of antihistaminic piperidine derivatives |
US6147216A (en) * | 1993-06-25 | 2000-11-14 | Merrell Pharmaceuticals Inc. | Intermediates useful for the preparation of antihistaminic piperidine derivatives |
WO1995010278A1 (en) * | 1993-10-15 | 1995-04-20 | Hoechst Marion Roussel, Inc. | Treatment of allergic disorders with terfenadine carboxylate |
DE69426306T2 (de) * | 1993-10-25 | 2001-06-07 | Merrell Pharma Inc | Stabile pharmazeutische zubereitungen, die terfenadine und ibuprofen enthalten |
WO1995031436A1 (en) * | 1994-05-16 | 1995-11-23 | Merrell Pharmaceuticals Inc. | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC α-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS |
CN1148849A (zh) * | 1994-05-18 | 1997-04-30 | 赫彻斯特马里恩鲁斯公司 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
CN101497581B (zh) * | 1994-05-18 | 2012-07-11 | 安万特萨博Ⅱ有限公司 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
MX9701305A (es) | 1994-08-25 | 1998-05-31 | Merrell Pharma Inc | Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas. |
EP0812195B1 (en) * | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
NZ306319A (en) * | 1995-05-08 | 1999-08-30 | Hoechst Marion Roussel Inc | 1-alkylphenyl substituted 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butanol derivatives and medicaments |
US5574045A (en) * | 1995-06-06 | 1996-11-12 | Hoechst Marion Roussel, Inc. | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form |
US5906747A (en) * | 1995-11-13 | 1999-05-25 | Biosepra Inc. | Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates |
US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
US6201124B1 (en) * | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US6153754A (en) * | 1995-12-21 | 2000-11-28 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
US5998439A (en) * | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
US5925761A (en) * | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
ES2216191T3 (es) * | 1997-03-11 | 2004-10-16 | Aventis Pharmaceuticals Inc. | Procedimiento para preparar acido 4-(4-(hidroxidifenil)-1-piperidinil)-1-hidroxibutil)-alfa,alfa-dimetilfenilacetico y derivados fosforilados. |
US6451815B1 (en) | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
KR100514264B1 (ko) * | 1997-08-26 | 2005-09-15 | 아벤티스 파마슈티칼스 인크. | 피페리디노알칸올-충혈완화제 조합용 제약 조성물 |
DK0924196T3 (da) * | 1997-12-17 | 2003-09-29 | Aventis Pharma Gmbh | Fremgangsmåde til alkylering af alkyl- eller benzylcyanderivater i nærværelse af trialkylaminer eller -phosphiner |
DK1041990T3 (da) * | 1997-12-23 | 2006-10-02 | Schering Corp | Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin |
US6194431B1 (en) | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
CN101311165B (zh) * | 1998-07-02 | 2011-05-18 | 安万特第二分公司 | 抗组胺哌啶衍生物及制备其的中间体 |
AU2007200674C1 (en) * | 1998-07-02 | 2011-02-24 | Aventisub Llc | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof |
US6673933B2 (en) | 1998-07-02 | 2004-01-06 | Aventis Pharmaceutical Inc. | Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
US6683094B2 (en) | 1998-07-02 | 2004-01-27 | Aventis Pharmaceuticals Inc. | Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
GB9822170D0 (en) * | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
IN191492B (no) * | 1999-05-25 | 2003-12-06 | Ranbaxy Lab Ltd | |
US6613906B1 (en) * | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
US6613907B2 (en) | 2000-11-08 | 2003-09-02 | Amr Technology, Inc. | Process for the production of piperidine derivatives with microorganisms |
CH695216A5 (de) * | 2001-02-23 | 2006-01-31 | Cilag Ag | Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes. |
PL366576A1 (en) * | 2001-04-09 | 2005-02-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of fexofenadine hydrochloride |
US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
EP2261209A1 (en) | 2001-06-18 | 2010-12-15 | Dr. Reddy's Laboratories Ltd. | Novel crystalline forms of 4-[4-[4- hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenene acetic acid and its hydrochloride |
US7700779B2 (en) * | 2001-06-18 | 2010-04-20 | Dr. Reddy's Laboratories Limited | Crystalline forms of fexofenadine and its hydrochloride |
EP1453509A2 (en) * | 2001-11-08 | 2004-09-08 | Teva Pharmaceutical Industries Ltd. | Polymorphs of fexofenadine base |
US20030158227A1 (en) * | 2001-11-08 | 2003-08-21 | Barnaba Krochmal | Polymorphs of fexofenadine base |
US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
ES2239554T1 (es) * | 2002-06-10 | 2005-10-01 | Teva Pharmaceutical Industries Ltd. | Forma xvi polimorfica de hidrocloruro de fexofenadina. |
US20060173042A1 (en) * | 2002-12-16 | 2006-08-03 | Sharma Mukesh K | Process for the preparation of fexofenadine |
CA2514610A1 (en) * | 2003-01-31 | 2004-08-12 | Ranbaxy Laboratories Limited | Process for the preparation of fexofenadine |
US20050026890A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
GB0319935D0 (en) * | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CA2560882A1 (en) * | 2004-04-26 | 2005-11-03 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of fexofenadine hydrochloride and processes for their preparation |
WO2006008567A1 (en) * | 2004-06-18 | 2006-01-26 | Wockhardt Limited | Pharmaceutical compositions for piperidinoalkanol compounds |
ITMI20041568A1 (it) * | 2004-07-30 | 2004-10-30 | Dipharma Spa | "polimorfi di fexofenadina base" |
US7498443B2 (en) * | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of carebastine |
US7498345B2 (en) * | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
WO2006037042A1 (en) * | 2004-09-28 | 2006-04-06 | Teva Pharmaceutical Industries Ltd. | Fexofenadine crystal form and processes for its preparation thereof |
EP2486942B1 (en) | 2004-11-24 | 2018-10-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
JP2008120684A (ja) * | 2005-03-07 | 2008-05-29 | Kumamoto Univ | 抗アレルギー薬 |
BRPI0614231A2 (pt) * | 2005-08-05 | 2012-12-11 | Lupin Ltd | composições farmacêuticas de fexofenadina em forma de suspensão oral |
US20080292584A1 (en) * | 2005-10-14 | 2008-11-27 | Mutual Pharmaceutical Company, Inc. | Metaxalone products, method of manufacture, and method of use |
US20070088065A1 (en) * | 2005-10-14 | 2007-04-19 | Jie Du | Metaxalone products, method of manufacture, and method of use |
WO2007049303A2 (en) * | 2005-10-28 | 2007-05-03 | Ind-Swift Laboratories Limited | An improved process for the preparation of highly pure fexofenadine |
NZ568694A (en) | 2005-11-09 | 2011-09-30 | Zalicus Inc | Method, compositions, and kits for the treatment of medical conditions |
DOP2006000274A (es) * | 2005-12-14 | 2007-10-15 | Sanofi Aventis Us Llc | Formulación de suspensión de fexofenadina |
CN100443470C (zh) * | 2006-07-21 | 2008-12-17 | 杭州保灵有限公司 | 一种依巴斯汀的制备方法 |
ITMI20061491A1 (it) * | 2006-07-27 | 2008-01-28 | Archimica Srl | Processo per la preparazione di fexofenadina. |
ITMI20061492A1 (it) * | 2006-07-27 | 2008-01-28 | Archimica Srl | Processo per la preparazione di fexofenadina. |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
CA2681267C (en) | 2007-04-13 | 2013-11-19 | Southern Research Institute | Anti-angiogenic agents and methods of use |
ITMI20070987A1 (it) * | 2007-05-16 | 2008-11-17 | Dipharma Francis Srl | Procedimento per la preparazione di composti chetonici |
US20090076080A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched fexofenadine |
US20090306135A1 (en) | 2008-03-24 | 2009-12-10 | Mukesh Kumar Sharma | Stable amorphous fexofenadine hydrochloride |
CA2724607A1 (en) * | 2008-05-30 | 2009-12-31 | Fairfield Clinical Trials, Llc | Method and composition for skin inflammation and discoloration |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
CN101585805B (zh) * | 2009-06-06 | 2011-07-06 | 浙江大学宁波理工学院 | 一种抗过敏药物非索非那定盐酸盐的制备方法 |
EP2289867A3 (en) | 2009-08-19 | 2012-04-25 | Jubilant Organosys Limited | A process for producing 4-(4-halo-1-oxybutyl)-alpha,alpha-dimethylbenzene acetic acid or alkyl esters thereof |
CN101671292B (zh) * | 2009-10-10 | 2011-09-07 | 浙江大学宁波理工学院 | 盐酸非索非那定的合成方法 |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
EP2371817A1 (en) * | 2010-04-01 | 2011-10-05 | Arevipharma GmbH | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
ES2403130B1 (es) | 2010-06-15 | 2014-09-29 | Chemelectiva S.R.L. | Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación |
SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
AR088204A1 (es) | 2011-09-29 | 2014-05-14 | Shionogi & Co | Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
CN102659667B (zh) * | 2012-04-20 | 2013-08-14 | 浙江启明药业有限公司 | 一种非索非那定关键中间体的合成方法 |
CN103333100B (zh) * | 2013-06-06 | 2016-04-06 | 池州东升药业有限公司 | 一种盐酸非索非那定的合成工艺 |
ITMI20131652A1 (it) | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | Procedimento per la purificazione di derivati dell'acido 2-fenil-2-metil-propanoico |
CN104557671B (zh) * | 2013-10-10 | 2018-04-13 | 池州东升药业有限公司 | 一种非索非那定及中间体的合成方法 |
EP2949321A1 (en) | 2014-05-26 | 2015-12-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer formulations of fexofenadine and montelukast |
DK3247699T3 (da) | 2015-01-22 | 2019-08-12 | Sanofi Aventis Deutschland | Proces til produktion of 2-[4-(cyclopropancarbonyl)phenyl]-2-methyl-propannitril |
HUE047669T2 (hu) | 2015-10-22 | 2020-05-28 | Sanofi Aventis Deutschland | Eljárás fexofenadin és az eljárásban használt köztitermékek elõállítására |
GB202212656D0 (en) | 2022-08-31 | 2022-10-12 | Novumgen Ltd | An orodispersible tablet of fecofenadine and it process of preparation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1242169A (en) * | 1969-04-09 | 1971-08-11 | Ucb Sa | Piperidine derivatives |
US3965257A (en) * | 1972-01-28 | 1976-06-22 | Richardson-Merrell Inc. | Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions |
BE794596A (fr) * | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Piperidinoalcanone-oximes substituees et leur procede de preparation |
US3806526A (en) * | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
BE794598A (fr) * | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation |
ZA728544B (en) * | 1972-01-28 | 1974-02-27 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US3941795A (en) * | 1974-02-08 | 1976-03-02 | Richardson-Merrell Inc. | α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES |
US3931197A (en) * | 1974-02-08 | 1976-01-06 | Richardson-Merrell Inc. | Substituted piperidine derivatives |
US3946022A (en) * | 1974-03-04 | 1976-03-23 | Richardson-Merrell Inc. | Piperidine derivatives |
US3922276A (en) * | 1974-12-11 | 1975-11-25 | Robins Co Inc A H | 1-Substituted-4-benzylidenepiperidines |
US3956296A (en) * | 1974-12-11 | 1976-05-11 | A. H. Robins Company, Incorporated | 1-Substituted-4-benzylpiperidines |
-
1979
- 1979-04-10 US US06/028,813 patent/US4254129A/en not_active Expired - Lifetime
-
1980
- 1980-01-18 CA CA344,020A patent/CA1123438A/en not_active Expired
- 1980-01-18 IL IL59158A patent/IL59158A/xx unknown
- 1980-01-18 NZ NZ192653A patent/NZ192653A/xx unknown
- 1980-01-21 ZA ZA00800332A patent/ZA80332B/xx unknown
- 1980-01-29 AU AU55016/80A patent/AU531146B2/en not_active Expired
- 1980-02-07 NL NL8000754A patent/NL190580C/xx not_active IP Right Cessation
- 1980-02-28 DE DE19803007498 patent/DE3007498A1/de active Granted
- 1980-03-05 CH CH174180A patent/CH643245A5/de not_active IP Right Cessation
- 1980-03-17 AT AT0144880A patent/AT376208B/de not_active IP Right Cessation
- 1980-03-24 IT IT48245/80A patent/IT1143960B/it active Protection Beyond IP Right Term
- 1980-03-26 ES ES489934A patent/ES8103735A1/es not_active Expired
- 1980-03-27 DK DK132980A patent/DK153709C/da not_active IP Right Cessation
- 1980-03-28 PH PH23831A patent/PH17023A/en unknown
- 1980-04-08 SE SE8002634A patent/SE448726B/sv not_active IP Right Cessation
- 1980-04-09 FR FR8007992A patent/FR2453854A1/fr active Granted
- 1980-04-09 BE BE0/200161A patent/BE882703A/fr not_active IP Right Cessation
- 1980-04-09 NO NO801014A patent/NO154521C/no unknown
- 1980-04-09 JP JP4577180A patent/JPS55141469A/ja active Granted
-
1998
- 1998-04-08 NL NL980013C patent/NL980013I2/nl unknown
- 1998-05-29 NO NO1998017C patent/NO1998017I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO154521B (no) | Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater. | |
NO154964B (no) | Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive piperidinderivater. | |
US4285957A (en) | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof | |
US4285958A (en) | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof | |
US3878217A (en) | Alpha-aryl-4-substituted piperidinoalkanol derivatives | |
TW474932B (en) | Novel piperidines | |
US3965257A (en) | Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions | |
US20010025106A1 (en) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof | |
US3946022A (en) | Piperidine derivatives | |
NO754180L (no) | ||
NO163395B (no) | Stroemkilde for lysbuesveisning. | |
NO309765B1 (no) | Difenylmetylen-piperidin-derivater, anvendelse av og farmasöytiske blandinger inneholdende dem og fremgangsmåte for fremstilling derav | |
NO750394L (no) | ||
NO803453L (no) | Fremgangsmaate ved fremstilling av piperidylbenzimidazolonderivater | |
JPS6341901B2 (no) | ||
JPS62273969A (ja) | 1,4−二置換ピペラジン誘導体、これを含む薬剤組成物およびその製造方法 | |
US4086347A (en) | 9-[3-(4-Phenoxymethylpiperidino)-propyl]-adenines | |
US4443462A (en) | Antipsychotic 4-(naphthalenyloxy)piperidine derivatives | |
US4180583A (en) | Olefinic 4-substituted piperidino derivatives as therapeutics | |
US6518282B1 (en) | 4-Arylpiperidine derivatives for the treatment of pruritus | |
US4188396A (en) | New phenylazacycloalkanes | |
NO135248B (no) | ||
IE49998B1 (en) | 4-(naphthalenyloxy)piperidine derivatives | |
EP0052311A1 (en) | 1-((Benzoylphenyl) - lower-alkyl) piperidines and carbinol analogs and preparation thereof | |
EP0234098A1 (en) | N-[piperidylaminocarbonyl]quinolinecarboxamide derivatives having psychotropic activity |